Elanco Animal Health Incorporated Common Stock (ELAN)
26.18
+3.19 (13.88%)
NYSE · Last Trade: May 6th, 10:55 PM EDT
Detailed Quote
| Previous Close | 22.99 |
|---|---|
| Open | 23.25 |
| Bid | 26.11 |
| Ask | 26.24 |
| Day's Range | 22.86 - 26.29 |
| 52 Week Range | 9.420 - 27.72 |
| Volume | 12,365,373 |
| Market Cap | 12.94B |
| PE Ratio (TTM) | -54.54 |
| EPS (TTM) | -0.5 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 4,733,220 |
Chart
About Elanco Animal Health Incorporated Common Stock (ELAN)
Elanco Animal Health Inc is a global leader in the development and manufacturing of products for animal health and well-being. The company focuses on providing innovative solutions for companion and livestock animals, which include a wide range of vaccines, pharmaceuticals, and nutritional products designed to prevent and treat diseases. By combining science and technology, Elanco aims to enhance animal care and improve food safety while promoting sustainable farming practices. With a commitment to animal health and welfare, the company partners with veterinarians, farmers, and pet owners to deliver effective health management solutions. Read More
News & Press Releases
Elanco (ELAN) Q1 2026 Earnings Transcript
Via The Motley Fool · May 6, 2026
Animal health company Elanco (NYSE:ELAN) announced better-than-expected revenue in Q1 CY2026, with sales up 14.9% year on year to $1.37 billion. The company ...
Via StockStory · May 6, 2026
Elanco Animal Health (NYSE:ELAN) Soars After Strong Q1 Beat, Raises Full-Year Outlookchartmill.com
Via Chartmill · May 6, 2026
Animal health company Elanco (NYSE:ELAN) will be reporting results this Wednesday before the bell. Here’s what investors should know. Elanco beat analysts’ r...
Via StockStory · May 4, 2026
Elanco Animal Health Inc (NYSE:ELAN) Reports Strong Q4 Earnings Beat and Confirms 2026 Guidancechartmill.com
Via Chartmill · February 24, 2026
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the pharmaceuticals stocks, including Elanco (NYSE:ELAN) and its peers. The pharmaceuti...
Via StockStory · April 22, 2026
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...
Via StockStory · April 13, 2026
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...
Via StockStory · April 6, 2026
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
Via StockStory · March 27, 2026
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have...
Via StockStory · March 23, 2026
Elanco’s 26.6% return over the past six months has outpaced the S&P 500 by 23.6%, and its stock price has climbed to $23.47 per share. This was partly thanks...
Via StockStory · March 12, 2026
What Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the hea...
Via StockStory · March 6, 2026
The United States Department of Agriculture (USDA) has officially greenlit a massive $100 million initiative dubbed the "Screwworm Challenge," aimed at neutralizing a resurgent biological threat that hasn't plagued the American mainland in over half a century. As of March 2, 2026, federal authorities and state governments, led by Texas,
Via MarketMinute · March 2, 2026
Shares of animal health company Elanco (NYSE:ELAN)
jumped 8.2% in the morning session after the company reported fourth-quarter results that surpassed Wall Street's expectations, with investors focusing on strong current performance over a mixed outlook for 2026. For the quarter,
Via StockStory · February 24, 2026

Elanco (ELAN) Q4 2025 Earnings Call Transcript
Via The Motley Fool · February 24, 2026
Animal health company Elanco (NYSE:ELAN) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 12.2% year on year to $1.14 billion. Guidance for next quarter’s revenue was better than expected at $1.29 billion at the midpoint, 1% above analysts’ estimates. Its non-GAAP profit of $0.13 per share was 15.6% above analysts’ consensus estimates.
Via StockStory · February 24, 2026
Animal health company Elanco (NYSE:ELAN)
will be reporting earnings this Tuesday before market open. Here’s what you need to know.
Via StockStory · February 22, 2026

This U.S. supplier serves construction and packaging markets with a diverse mix of cement, aggregates, wallboard, and paperboard.
Via The Motley Fool · February 14, 2026

FTI Consulting provides business advisory services worldwide, specializing in transformation, risk mitigation, and dispute resolution.
Via The Motley Fool · February 14, 2026

This enterprise software provider delivers cloud-based AI solutions for customer engagement, compliance, and financial crime prevention.
Via The Motley Fool · February 14, 2026
Zoetis Inc. (NYSE: ZTS) stands today as the undisputed global leader in animal health, a position it has fortified since its historic decoupling from Pfizer over a decade ago. As of February 12, 2026, the company finds itself at a pivotal crossroads. While it continues to dominate the multi-billion dollar markets for companion animal medicines [...]
Via Finterra · February 12, 2026
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Via StockStory · February 11, 2026
In a decisive move to protect the nation’s multi-billion dollar livestock industry, U.S. Secretary of Agriculture Brooke Rollins announced today, February 5, 2026, the launch of a $100 million "New World Screwworm Grand Challenge." The federal initiative is designed to spur rapid innovation in the detection, containment, and
Via MarketMinute · February 5, 2026
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages.
Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Via StockStory · January 26, 2026
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities.
However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
Via StockStory · January 25, 2026